This study aims to generate structured patient preference evidence on prophylactic treatment options for haemophilia A for adults with and without inhibitors to support health technology assessment and benefit evaluation processes. The study will examine how individuals with haemophilia A evaluate trade-offs between treatment effectiveness, safety, and treatment administration characteristics when choosing between prophylactic therapies. Participants will repeatedly choose between hypothetical treatment profiles that differ in clinically relevant attributes and levels.

Inclusion Criteria:

• Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
• Participant has the mental capacity and sufficient German language proficiency to understand the study procedures and to complete the survey.
• Age above or equal to 18 years at the time of signing informed consent.
• Validated diagnose with haemophilia A, with and without inhibitors.
• Resident in Germany.

Exclusion Criteria:

• No provision of informed consent in this study.
• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
• Age below 18 years at the time of signing informed consent.
• Absence of a diagnosis of haemophilia A.
• No residence in Germany.

Adults with haemophilia A with and without inhibitors

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com